Lucira Health, Inc. (NASDAQ:LHDX – Get Rating)'s share price dropped 9.9% during trading on Tuesday . The company traded as low as $0.20 and last traded at $0.23. Approximately 525,450 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 29,320,967 shares. The stock had previously closed at $0.25.

Lucira Health Stock Up 5.2 %

The company has a debt-to-equity ratio of 0.48, a current ratio of 1.46 and a quick ratio of 0.79. The business has a 50 day moving average price of $0.33 and a 200 day moving average price of $0.58. The firm has a market capitalization of $9.75 million, a P/E ratio of -0.07 and a beta of 3.75.

Hedge Funds Weigh In On Lucira Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new position in Lucira Health during the second quarter valued at about $32,000. Renaissance Technologies LLC bought a new position in Lucira Health during the second quarter valued at about $78,000. BlackRock Inc. increased its stake in Lucira Health by 18.8% during the first quarter. BlackRock Inc. now owns 51,468 shares of the company's stock valued at $183,000 after acquiring an additional 8,131 shares during the period. AlphaCentric Advisors LLC bought a new position in Lucira Health during the third quarter valued at about $339,000. Finally, Vanguard Group Inc. increased its stake in Lucira Health by 23.4% during the first quarter. Vanguard Group Inc. now owns 631,767 shares of the company's stock valued at $2,256,000 after acquiring an additional 119,929 shares during the period. 57.02% of the stock is currently owned by institutional investors.

Lucira Health Company Profile

(Get Rating)

Lucira Health, Inc, a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits.

See Also

• Get a free copy of the StockNews.com research report on Lucira Health (LHDX)
• The Squeeze Is On For EVGo, Rally To Follow
• Is The Bottom In For RH, Or Is This Just A Stopping Point?
• Dividend King H.B. Fuller Signals Slowing In 2023
• Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
• 3 Companies That Just Started Paying Dividends

Receive News & Ratings for Lucira Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucira Health and related companies with MarketBeat.com's FREE daily email newsletter.